

Utility Patent Application Transmittal

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket Number

UCAL107DIV

First Named Inventor

BISTRUP

Title

GLYCOSYL SULFOTRANSFERASE
3

Express Mail Label No.

EL923479227US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

ADDRESS TO:

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☐ Fee Transmittal Form (e.g., PTO/SB/17)

(Submit an original and a duplicate for fee processing)

2. ☐ Applicant claims small entity status.

See 37 CFR 1.27.

3. ☒ Specification
(preferred arrangement set forth below)

Total
Pages

62

- Descriptive title of the invention
- Cross Reference to Related Applications
- Statement Regarding Fed sponsored R&D
- Reference to sequence listing, a table, or a computer program listing appendix
- Background of the invention
- Brief Summary of the invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claims(s)
- Abstract of the Disclosure

4. ☒ Drawing(s) (35 U.S.C. 113)

Total
Sheets
Total
Pages

15

5. Oath or Declaration

a. ☐ Newly executed (original or copy)

b. ☒ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 18 completed)

i. ☐ **DELETION OF INVENTOR(S)**

Signed statement attached deleting
inventor(s) named in the prior application, see
37 CFR 1.63(d)(2) and 1.33(b)

6. ☒ Application Data Sheet, See 37 CFR 1.76

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer
Program (Appendix)

8. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)

a. ☐ Computer Readable Form (CRF)

b. Specification Sequence Listing on:

i. ☐ CD-Rom or CD-R (2 copies); or

ii. ☐ Paper

c. ☐ Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. ☒ Assignment Papers (cover sheet & documents(s))

10. ☐ 37 CFR 3.73(b) Statement
(when there is an assignee) ☒ Power of
Attorney

11. ☐ English Translation Document (if applicable)

12. ☒ Information Disclosure
Statement (IDS)/PTO-1449 ☐ Copies of IDS
Citations

13. ☒ Preliminary Amendment

14. ☒ Return Receipt Postcard (MPEP 503)
(should be specifically itemized)

15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)

16. ☐ Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i).
Applicant must attach form PTO/SB/35 or its equivalent

17. ☒ Other: 1) Associate Power of Attorney (1 pg.)
2) Notification of Prior Sequence Listing (1 pg.)

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation

☒ Divisional

☐ Continuation-in-part (CIP)

of prior application No

09/190,911

Prior Application Information

Examiner

M. Moran

Group Art Unit

1631

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

Fee Calculation

CLAIMS AS FILED

For	#Filed	# Allowed	#Extra	Rate	Fee
Total Claims	20	20	0	x 18	\$0.00
Indep. Claims	3	3	0	x 84	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					
TOTAL CLAIM FEES					
BASIC FILING FEE					\$740.00
OTHER FEE (specify purpose) Two (2) Assignment Recordations					\$80.00
TOTAL					\$820.00

The Commissioner is authorized to charge any fees which may be required, or credit any overpayment to Deposit Account 50-0815. If additional fees are required, including extensions of time, please consider this a petition therefore. A duplicate copy of this sheet is enclosed.

Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)

19. ☐ Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

Warning

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director

of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application

being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

19. CORRESPONDENCE ADDRESS




Customer Number or
Bar Code Label

(Insert Customer Number or Bar Code Label here)

24353



Correspondence Address below

Name (Print/Type)	Paula A. Borden	Registration No.	42,344
Signature		Date	11-08-2001
Firm Name	Bozicevic, Field & Francis LLP	Address	200 Middlefield Road, Suite 200
City	Menlo Park	State	California
		zip	94025
Telephone - Direct Dial	650-833-7710	Fax	650-327-3231

NOTIFICATION OF PRIOR SEQUENCE LISTING

Application Number	To Be Assigned
Confirmation Number	To Be Assigned
Filing Date	November 8, 2001
First Named Inventor	BISTRUP
Examiner	To Be Assigned
Group Art	To Be Assigned
Attorney Docket No.	UCAL107DIV

ADDRESS TO: Assistant Commissioner for Patents
Washington, D.C. 20231


Sir:

The above-identified patent application contains sequences of nucleic acid and polypeptides. A sequence listing was prepared for parent application, **Serial No. 09/190,911, filed November 12, 1998**, in paper and computer-readable format. The sequences in the present application are identical to those presented in the parent application. Therefore, please transfer to this application, in accordance with 37 CFR 1.821(e), the computer readable copy from applicants' other application.

Applicants respectfully submit that the present patent application is now in compliance with 37 CFR 1.821 - 1.825.

The Commissioner is authorized to charge any fees which may be required, or credit any overpayment to Deposit Account 50-0815. If additional fees are required, including extensions of time, please consider this a petition therefore.


SIGNATURE OF APPLICANT, ATTORNEY OR AGENT REQUIRED

Name (Print/Type)	Paula A. Borden		Registration No.	42,344	
Signature			Date	11-08-2001	
Firm Name	Bozicevic, Field & Francis LLP		Address	200 Middlefield Road, Suite 200	
City	Menlo Park	State	California	zip	94025
Telephone - Direct Dial	650-833-7710		Facsimile	650-327-3231	

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage

Via Express Mail bearing Express Mail No. EL923479227US in an envelope addressed to: Commissioner for Patents, Washington, DC 20231.

Name (Print/Type)	Margaret Pierce	Signature		Date	11/8/2001
-------------------	-----------------	-----------	--	------	-----------